跳至主要内容
临床试验/NCT02706821
NCT02706821已完成不适用

An Eight-week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Persimmon Leaf Extract on Anti-diabetes

Chonbuk National University Hospital0 个研究点目标入组 34 人开始时间: 2014年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
34
主要终点
Fasting and postprandial plasma glucose

研究概览

简要总结

The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose. The investigators measures changes in diabetes associated parameters, including fasting blood glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 20-75 years
  • Fasting blood glucose (FPG) 100~140 mg/dL or postprandial blood glucose (PPG) 140~250 mg/dL

排除标准

  • FPG more than 140 mg/dL
  • 2h PPG more than 200 mg/dL
  • Type 1 diabetes or HbA1c more than 9.0%
  • treatment with corticosteroids within the past 4 weeks
  • cardiovascular disease

结局指标

主要结局

Fasting and postprandial plasma glucose

时间窗: baseline day 57, 85 and 141

次要结局

  • Interleukin-6 (IL-6)(baseline and day 57, 85 and 141)
  • resistin(baseline and day 57, 85 and 141)
  • Glycated hemoglobin (HbA1c)(baseline and day 57, 85 and 141)
  • adiponectin(baseline and day 57, 85 and 141)
  • leptin(baseline and day 57, 85 and 141)
  • Fasting plasma insulin(baseline and day 57, 85 and 141)
  • Tumor necrosis factor alpha (TNF-α)(baseline and day 57, 85 and 141)
  • Monocyte chemoattractant protein-1 (MCP-1)(baseline and day 57, 85 and 141)
  • C-peptide(baseline and day 57, 85 and 141)
  • Markers of Inflammation(baseline and day 57, 85 and 141)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Soo-Wan Chae

Professor

Chonbuk National University Hospital

相似试验

Anti-diabetic Effects of Persimmon Leaf Extract | 临床试验